Clinical Trial Update: Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating alisporivir added to peginterferon alfa-2a and ribavirin in chronic hepatitis C genotype 1 patients who relapsed or did not respond to …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Alisporivir (DEB025) (alisporivir)
• Peginterferon alfa-2a (peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Debiopharm International SA | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2016-08-25